During the past decade, Hallym University Kangnam Sacred Heart Hospital conducted 64 clinical trials. In the 10-year time frame, 64 clinical trials started and 18 clinical trials were completed, i.e. on average, 28.1% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 16 clinical trials were completed. i.e. 59.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hallym University Kangnam Sacred Heart Hospital" #1 sponsor was "Hallym University Kangnam Sacred Heart Hospital" with 16 trials, followed by "Pfizer" with 9 trials sponsored, "Eli Lilly and Company" with 7 trials sponsored, "Janssen Research & Development, LLC" with 5 trials sponsored and "Bayer" with 5 trials sponsored. Other sponsors include 33 different institutions and companies that sponsored additional 35 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hallym University Kangnam Sacred Heart Hospital" #1 collaborator was "CardioVascular Research Foundation, Korea" with 3 trials as a collaborator, "Ajou University School of Medicine" with 2 trials as a collaborator, "Dermira, Inc." with 2 trials as a collaborator, "Hallym University Kangnam Sacred Heart Hospital" with 2 trials as a collaborator and "Incyte Corporation" with 2 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Hallym University Kangnam Sacred Heart Hospital" are "Atopic Dermatitis" (6 trials), "COVID-19" (4 trials), "Dermatitis, Atopic" (3 trials), "Hepatitis B" (3 trials) and "Influenza A" (3 trials). Many other conditions were trialed in "Hallym University Kangnam Sacred Heart Hospital" in a lesser frequency.

Most popular intervention types in "Hallym University Kangnam Sacred Heart Hospital" are "Drug" (45 trials), "Other" (13 trials), "Biological" (10 trials), "Device" (5 trials) and "Behavioral" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Baricitinib" (2 trials), "Clevudine" (2 trials), "Finerenone (BAY94-8862)" (2 trials) and "Lebrikizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hallym University Kangnam Sacred Heart Hospital" are 67 trials for "All" genders, 6 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Hallym University Kangnam Sacred Heart Hospital". undefined are not yet recruiting, 8 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 46 completed trials in Hallym University Kangnam Sacred Heart Hospital, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Hallym University Kangnam Sacred Heart Hospital, 2 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 13 trials, and there were also 14 trials that are defined as “Not Applicable".